Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade

Frontiers in Immunology(2022)10.3389/fimmu.2022.794684Source: DataRank Database

B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.58)OA: goldTopics (53)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Jason Roszik ORCID,Neeraj K. Saini ORCID,Vipul Kumar Singh ORCID,Karishma Bavisi,Zhiqiang Wang ORCID

Live enrichment

PubMed:35720386 PMC:PMC9204262 OpenAlex:https://openalex.org/W4281618099

NCI NIH HHS

Grant: P30 CA016672

NCI NIH HHS

Grant: P50 CA093459

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5P50CA093459-03

UT M.D. Anderson Cancer Center SPORE in Melanoma

FWCI

1.58

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.794684/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.794684/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2022.794684/full

journalhttps://doi.org/10.3389/fimmu.2022.794684

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35720386

Fields of Study

Immunotherapy and Immune ResponsesCAR-T cell therapy researchCancer Immunotherapy and Biomarkers0301 basic medicine03 medical and health sciences

MeSH Terms

AnimalsAntibodiesHumansImmunotherapyMelanoma, ExperimentalMice, Inbred C57BLCD8-Positive T-LymphocytesToll-Like Receptor 7MiceTumor Microenvironment

Keywords

MelanomaCD8Immune checkpointCancer researchImmunityImmunologyCytotoxic T cellImmune systemT cellMedicineCD40CD19BlockadeB cellImmunotherapyAntibodyBiologyReceptorInternal medicineIn vitroCytotoxic T-lymphocyte-associated Protein 4 (Ctla-4)Programmed Death-ligand 1 (Pd-l1)Toll-like Receptor 7/8Knockout (Ko)BlymphocytesChemokinecxcl13The Cancer Genome Atlas Melanoma (Tcga)Melanoma, ExperimentalRC581-607CD8-Positive T-LymphocytesAntibodiesMice, Inbred C57BLMiceToll-Like Receptor 7Tumor MicroenvironmentAnimalsHumansImmunologic diseases. Allergy

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade

FAIR Checklist

Authors (16)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)